Evidence map›Paper›PMID 41402710›Full record

ArticleCellular & molecular biology letters2025

The cancer-testis lncRNA LINC01940 promotes gastric cancer malignant progression and chemoresistance by enhancing ribosome biogenesis via TAF15-mediated NOL11 SUMOylation.

Weijie Zang, Debiao Fan, Zhuang Lu, Xian Gao, Danjie Xing, Guangze Zhang, Lei Liu, Jianfeng Yi, Junjie Chen, Yilin Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Weijie ZangDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Debiao FanDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Zhuang LuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Xian GaoDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Danjie XingDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Guangze ZhangDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Lei LiuResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Jianfeng YiDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China.
Junjie ChenResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China. ntfyCJJ@ntu.edu.cn.
Yilin HuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China. hyl510@ntu.edu.cn.
Wanjiang XueDepartment of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, 20 Xisi Street, Nantong, 226001, Jiangsu, China. xuewanjiang@ntu.edu.cn.

Funding

grants from Jiangsu Provincial Research Hospital YJXYY202204-2-YSB23grants from Jiangsu Provincial Research Hospital YJXYY202204-2-YSC16grants from Jiangsu Provincial Research Hospital YJXYY202204-ZD18National Natural Science Foundation of China 82102720National Natural Science Foundation of China 82473448Natural Science Foundation of Jiangsu Province BK20220605Natural Science Foundation of Nantong JC2023092Natural Science Foundation of the Jiangsu Province, China BK20221272Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX24_3580
6 · The paper itself

Abstract

backgroundAberrant ribosome biogenesis promotes gastric cancer (GC) progression and contributes to chemoresistance by sustaining protein synthesis, upon which GC cell survival depends. However, the regulatory role of cancer-testis-associated long noncoding RNAs (CT-lncRNAs) in modulating ribosome biogenesis in GC remains largely unexplored.

methodsFirst, we performed a screening of lncRNAs and identified CT-lncRNA LINC01940 on the basis of integrated expression and survival analyses using The Cancer Genome Atlas (TCGA) data. Subsequently, the impact of LINC01940 on GC progression and chemosensitivity was evaluated using in vitro cell functional assays, patient-derived organoid models, and in vivo subcutaneous tumor xenograft experiments. To further elucidate the underlying mechanisms, we employed a comprehensive approach combining bioinformatics analyses, RNA sequencing, fluorescence in situ hybridization, translation assays, ribosomal DNA (rDNA) transcription assays, methylated RNA immunoprecipitation, co-immunoprecipitation mass spectrometry, fluorescence multiplex immunohistochemistry, and RNA pull-down mass spectrometry.

resultsNormally, testis-specific LINC01940 is aberrantly upregulated in GC and associated with poor prognosis. Functional assays demonstrated that LINC01940 promotes GC cell proliferation and invasion and confers resistance to cisplatin. Mechanistically, LINC01940 is stabilized by methyltransferase 16 (METTL16)/ insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3)-mediated N

conclusionsLINC01940 is a cancer-testis lncRNA that promotes GC progression and cisplatin resistance by enhancing ribosome biogenesis via the METTL16/IGF2BP3-TAF15-NOL11 axis. These findings suggest its potential as a prognostic biomarker and therapeutic target in GC.

Indexed as

Drug Resistance, NeoplasmNuclear ProteinsRibosomesRNA-Binding ProteinsRNA, Long NoncodingStomach NeoplasmsTATA-Binding Protein Associated FactorsTranscription Factor TFIIDAnimalsCell Line, TumorCell ProliferationCisplatinDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleCisplatinNuclear ProteinsRNA-Binding ProteinsRNA, Long NoncodingTATA-Binding Protein Associated FactorsTranscription Factor TFIIDCancer drug resistanceGastric cancerLINC01940Ribosome biogenesisSUMOylation

Identifiers

PMID41402710
PMCPMC12861072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.